Johnson & Johnson eyes blockbuster growth with Caplyta

Johnson & Johnson (NYSE: JNJ) is deepening its push into neuroscience with the acquisition of Intra-Cellular Therapies, completed in April 2025. The deal, first announced in January, brings Caplyta — a once-daily oral treatment for schizophrenia and bipolar depression — into the healthcare giant’s portfolio, in a move that signals a sharpened focus on mental health disorders.

Caplyta is projected to generate $758 million in revenue this year, accounting for around 10% of Johnson & Johnson’s Neuroscience segment. Analysts expect sales to hit $1.2 billion in 2026, with peak global revenue reaching $4.2 billion by 2034. At that point, the drug is forecast to contribute nearly half of the company’s neuroscience sales — a significant boost to the group’s third-largest therapeutic area after Oncology and Immunology.

The US Food and Drug Administration (FDA) is currently reviewing a supplemental new drug application (sNDA) to expand Caplyta’s use as an adjunctive treatment for major depressive disorder (MDD), one of the most prevalent mental health conditions. Approval could position Caplyta as a standard of care across a broader swathe of depressive disorders.

The acquisition also hands Johnson & Johnson a pipeline of central nervous system (CNS) treatments, including ITI-1284 — a Phase 2 candidate targeting generalized anxiety disorder and psychosis related to Alzheimer’s disease.